California, USA-based Lyell Immunopharma has entered into a definitive agreement to acquire privately-held US CAR-T company ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...

Viking Therapeutics plans to advance its obesity drug VK2735 to Phase III trials by late 2024, following Phase II results ...

Biostar Pharmaceuticals plans to raise funds through an IPO on the Hong Kong Stock Exchange, offering 14.6 million shares at ...

Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines ...

The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and ...

Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart ...

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. The UK ...

Intellia Therapeutics reported positive Phase II results for its CRISPR therapy NTLA-2002, showing an 81% reduction in ...